<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32638429</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-1128</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Medicinal research reviews</Title><ISOAbbreviation>Med Res Rev</ISOAbbreviation></Journal><ArticleTitle>Modern approaches in gene therapy of motor neuron diseases.</ArticleTitle><Pagination><StartPage>2634</StartPage><EndPage>2655</EndPage><MedlinePgn>2634-2655</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/med.21705</ELocationID><Abstract><AbstractText>Motor neuron disorders are a group of neurodegenerative diseases characterized by muscle weakness, loss of ambulation, respiratory insufficiency, leading to an early death. Spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis are the most common and fatal motor neuron diseases. The last 3 years became very successful for novel gene therapy approaches in SMA in infants. Two innovative drugs-nusinersen (Spinraza) and onasemnogene abeparvovec (Zolgensma) have been approved by health authorities. The numerous molecular and genetic overlaps between different neurodegenerative diseases are of great importance in the development of innovative therapeutic strategies, including viral vector therapy and RNA modulating approaches.</AbstractText><CopyrightInformation>&#xa9; 2020 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zakharova</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1072-9968</Identifier><AffiliationInfo><Affiliation>Sixth Neurology Department (Department of Neuroinfectious Diseases), Research Center of Neurology, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Res Rev</MedlineTA><NlmUniqueID>8103150</NlmUniqueID><ISSNLinking>0198-6325</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">antisense oligonucleotide therapy</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">motor neuron diseases</Keyword><Keyword MajorTopicYN="N">spinal muscular atrophy</Keyword><Keyword MajorTopicYN="N">viral vectors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32638429</ArticleId><ArticleId IdType="doi">10.1002/med.21705</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Kiernan MC . Motor neuron disease in 2017: progress towards therapy in motor neuron disease. Nat Rev Neurol. 2018;14(2):65-66.</Citation></Reference><Reference><Citation>Tosolini AP , Sleigh JN . Motor neuron gene therapy: lessons from spinal muscular atrophy for amyotrophic lateral sclerosis. Front Mol Neurosci. 2017;10:405.</Citation></Reference><Reference><Citation>Klug B , Celis P , Carr M , Reinhardt J . Regulatory structures for gene therapy medicinal products in the European Union. Methods Enzymol. 2012;507:337-354.</Citation></Reference><Reference><Citation>Deverman BE , Ravina BM , Bankiewicz KS , Paul SM , Sah DW . Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov. 2018;17(9):641-659.</Citation></Reference><Reference><Citation>Qu Y , Liu Y , Noor AF , Tran J , Li R . Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases. Neural Regen Res. 2019;14(6):931-938.</Citation></Reference><Reference><Citation>Artusi S , Miyagawa Y , Goins WF , Cohen JB , Glorioso JC . Herpes simplex virus vectors for gene transfer to the central nervous system. Diseases. 2018;6(3):74.</Citation></Reference><Reference><Citation>Lykken EA , Shyng C , Edwards RJ , Rozenberg A , Gray SJ . Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10(1):16.</Citation></Reference><Reference><Citation>Colella P , Ronzitti G , Mingozzi F . Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87-104.</Citation></Reference><Reference><Citation>Scarrott JM , Herranz-Mart&#xed;n S , Alrafiah AR , Shaw PJ , Azzouz M . Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2015;15(7):935-947.</Citation></Reference><Reference><Citation>Gray SJ , Woodard KT , Samulski RJ . Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv. 2010;1(4):517-534.</Citation></Reference><Reference><Citation>Chen YH , Chang M , Davidson BL . Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med. 2009;15(10):1215-1218.</Citation></Reference><Reference><Citation>McCown TJ . Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther. 2011;11(3):181-188.</Citation></Reference><Reference><Citation>Havens MA , Hastings ML . Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44(14):6549-6563.</Citation></Reference><Reference><Citation>Arechavala-Gomeza V , Khoo B , Aartsma-Rus A . Splicing modulation therapy in the treatment of genetic diseases. Appl Clin Genet. 2014;7:245-252.</Citation></Reference><Reference><Citation>Perrone B , La Cognata V , Sprovieri T , et al. Alternative splicing of ALS genes: misregulation and potential therapies. Cell Mol Neurobiol. 2020;40(1):1-14</Citation></Reference><Reference><Citation>Klim JR , Williams LA , Limone F , et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167-179</Citation></Reference><Reference><Citation>Deleavey GF , Damha MJ . Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937-954.</Citation></Reference><Reference><Citation>Geary RS , Norris D , Yu R , Bennett CF . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46-51.</Citation></Reference><Reference><Citation>Wobst HJ , Mack KL , Brown DG , Brandon NJ , Shorter J . The clinical trial landscape in amyotrophic lateral sclerosis-past, present, and future. Med Res Rev. 2020.1-33.</Citation></Reference><Reference><Citation>Tora MS , Keifer OP Jr. , Lamanna JJ , Boulis NM . The challenges of developing a gene therapy for amyotrophic lateral sclerosis. Expert Rev Neurother. 2017;17(4):323-325.</Citation></Reference><Reference><Citation>Lefebvre S , B&#xfc;rglen L , Reboullet S , et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165.</Citation></Reference><Reference><Citation>Lanfranco M , Vassallo N , Cauchi RJ . Spinal muscular atrophy: from defective chaperoning of snRNP assembly to neuromuscular dysfunction. Front Mol Biosci. 2017;4:41.</Citation></Reference><Reference><Citation>Nussbacher JK , Tabet R , Yeo GW , Lagier-Tourenne C . Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron. 2019;102(2):294-320.</Citation></Reference><Reference><Citation>Cacciottolo R , Ciantar J , Lanfranco M , et al. SMN complex member Gemin3 self-interacts and has a functional relationship with ALS-linked proteins TDP-43, FUS and Sod1. Sci Rep. 2019;9(1):18666.</Citation></Reference><Reference><Citation>Shan X , Chiang P-M , Price DL , Wong PC . Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A. 2010;107(37):16325-16330.</Citation></Reference><Reference><Citation>Tsuiji H , Iguchi Y , Furuya A , et al. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol Med. 2013;5(2):221-234.</Citation></Reference><Reference><Citation>Brenner D , Weishaupt JH . Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol. 2019;32(5):735-739.</Citation></Reference><Reference><Citation>Verhaart I , Robertson A , Leary R , et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017;264(7):1465-1473.</Citation></Reference><Reference><Citation>Farrar MA , Vucic S , Johnston HM , du Sart D , Kiernan MC . Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr. 2013;162(1):155-159.</Citation></Reference><Reference><Citation>Finkel RS , McDermott MP , Kaufmann P , et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810-817.</Citation></Reference><Reference><Citation>Foust KD , Wang X , McGovern VL , et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271-274.</Citation></Reference><Reference><Citation>Naryshkin NA , Weetall M , Dakka A , et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345(6197):688-693.</Citation></Reference><Reference><Citation>Finkel RS , Mercuri E , Darras BT , et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.</Citation></Reference><Reference><Citation>Finkel RS , Chiriboga CA , Vajsar J , et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017-3026.</Citation></Reference><Reference><Citation>Hach&#xe9; M , Swoboda KJ , Sethna N , et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol. 2016;31(7):899-906.</Citation></Reference><Reference><Citation>Singh NN , Howell MD , Androphy EJ , Singh RN . How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24(9):520-526.</Citation></Reference><Reference><Citation>Chiriboga CA , Swoboda KJ , Darras BT , et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890-897.</Citation></Reference><Reference><Citation>Aragon-Gawinska K , Seferian AM , Daron A , et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology. 2018;91(14):e1312-e1318.</Citation></Reference><Reference><Citation>Ramdas S , Servais L . New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21(3):307-315.</Citation></Reference><Reference><Citation>Al-Zaidy SA , Mendell JR . From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol. 2019;100:3-11.</Citation></Reference><Reference><Citation>Schorling DC , Becker J , Pechmann A , Langer T , Wirth B , Kirschner J . Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2019;93(6):267-269.</Citation></Reference><Reference><Citation>Agosta F , Al-Chalabi A , Filippi M , et al. The El Escorial criteria: strengths and weaknesses. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):1-7.</Citation></Reference><Reference><Citation>Brown RH , Al-Chalabi A . Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172.</Citation></Reference><Reference><Citation>Hulisz D . Disease state overview. Am J Manag Care. 2018;24(15):S320-S326.</Citation></Reference><Reference><Citation>Burk K , Pasterkamp RJ . Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol. 2019;137(6):859-877.</Citation></Reference><Reference><Citation>van Rheenen W , Shatunov A , Dekker AM , et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48(9):1043-1048.</Citation></Reference><Reference><Citation>Wu CH , Fallini C , Ticozzi N , et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488(7412):499-503.</Citation></Reference><Reference><Citation>Al-Chalabi A , Andersen PM , Nilsson P , et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Gen. 1999;8(2):157-164.</Citation></Reference><Reference><Citation>Smith BN , Ticozzi N , Fallini C , et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84(2):324-331.</Citation></Reference><Reference><Citation>Cirulli ET , Lasseigne BN , Petrovski S , et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347(6229):1436-1441.</Citation></Reference><Reference><Citation>Brenner D , M&#xfc;ller K , Wieland T , et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139(Pt 5):e28.</Citation></Reference><Reference><Citation>Kim HJ , Kim NC , Wang YD , et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467-473.</Citation></Reference><Reference><Citation>Rosen DR , Siddique T , Patterson D , et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59-62.</Citation></Reference><Reference><Citation>DeJesus-Hernandez M , Mackenzie IR , Boeve BF , et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.</Citation></Reference><Reference><Citation>Sreedharan J , Blair IP , Tripathi VB , et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668-1672.</Citation></Reference><Reference><Citation>Kwiatkowski TJ Jr. , Bosco DA , Leclerc AL , et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205-1208.</Citation></Reference><Reference><Citation>Vance C , Rogelj B , Hortob&#xe1;gyi T , et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208-1211.</Citation></Reference><Reference><Citation>Renton AE , Chi&#xf2; A , Traynor BJ . State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17-23.</Citation></Reference><Reference><Citation>McCord JM , Fridovich I . The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. The. J Biol Chem. 1969;244(22):6056-6063.</Citation></Reference><Reference><Citation>Zou ZY , Zhou ZR , Che CH , Liu CY , He RL , Huang HP . Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88(7):540-549.</Citation></Reference><Reference><Citation>Neumann M , Sampathu DM , Kwong LK , et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133.</Citation></Reference><Reference><Citation>Buratti E , Baralle FE . Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 2008;13:867-878.</Citation></Reference><Reference><Citation>Harrison AF , Shorter J . RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474(8):1417-1438.</Citation></Reference><Reference><Citation>Deshaies JE , Shkreta L , Moszczynski AJ , et al. TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain. 2018;141(5):1320-1333.</Citation></Reference><Reference><Citation>Butti Z , Patten SA . RNA dysregulation in amyotrophic lateral sclerosis. Front Genet. 2018;9:712.</Citation></Reference><Reference><Citation>Torres P , Ram&#xed;rez-N&#xfa;&#xf1;ez O , Romero-Guevara R , et al. Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue. Autophagy. 2018;14(8):1398-1403.</Citation></Reference><Reference><Citation>Van Deerlin VM , Leverenz JB , Bekris LM , et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008;7(5):409-416.</Citation></Reference><Reference><Citation>Gromicho M , Oliveira Santos M , Pinto A , Pronto-Laborinho A , De Carvalho M . Young-onset rapidly progressive ALS associated with heterozygous FUS mutation. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(5-6):451-453.</Citation></Reference><Reference><Citation>Lagier-Tourenne C , Polymenidou M , Hutt KR , et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15(11):1488-1497.</Citation></Reference><Reference><Citation>Colombrita C , Onesto E , Buratti E , et al. From transcriptomic to protein level changes in TDP-43 and FUS loss-of-function cell models. Biochim Biophys Acta. 2015;1849(12):1398-1410.</Citation></Reference><Reference><Citation>Lattante S , Rouleau GA , Kabashi E . TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. Hum Mutat. 2013;34(6):812-826.</Citation></Reference><Reference><Citation>Shang Y , Huang EJ . Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis. Brain Res. 2016;1647:65-78.</Citation></Reference><Reference><Citation>Nomura T , Watanabe S , Kaneko K , Yamanaka K , Nukina N , Furukawa Y . Intranuclear aggregation of mutant FUS/TLS as a molecular pathomechanism of amyotrophic lateral sclerosis. J Biol Chem. 2014;289(2):1192-1202.</Citation></Reference><Reference><Citation>Feuillette S , Delarue M , Riou G , et al. Neuron-to-neuron transfer of FUS in drosophila primary neuronal culture is enhanced by ALS-associated mutations. J Mol Neurosci. 2017;62(1):114-122.</Citation></Reference><Reference><Citation>Lee S , Kim HJ . Prion-like mechanism in amyotrophic lateral sclerosis: are protein aggregates the key? Exp Neurobiol. 2015;24(1):1-7.</Citation></Reference><Reference><Citation>Prudencio M , Belzil VV , Batra R , et al. Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. Nat Neurosci. 2015;18(8):1175-1182.</Citation></Reference><Reference><Citation>Martier R , Liefhebber JM , Garc&#xed;a-Osta A , et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids. 2019;16:26-37.</Citation></Reference><Reference><Citation>Koppers M , Blokhuis AM , Westeneng HJ , et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann Neurol. 2015;78(3):426-438.</Citation></Reference><Reference><Citation>O'Rourke JG , Bogdanik L , Muhammad A , et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron. 2015;88(5):892-901.</Citation></Reference><Reference><Citation>Klim JR , Vance C , Scotter EL . Antisense oligonucleotide therapies for amyotrophic lateral sclerosis: existing and emerging targets. Int J Biochem Cell Biol. 2019;110:149-153.</Citation></Reference><Reference><Citation>Smith RA , Miller TM , Yamanaka K , et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest. 2006;116(8):2290-2296.</Citation></Reference><Reference><Citation>Miller TM , Pestronk A , David W , et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435-442.</Citation></Reference><Reference><Citation>Zhang K , Donnelly CJ , Haeusler AR , et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56-61.</Citation></Reference><Reference><Citation>Yamada SB , Gendron TF , Niccoli T , et al. RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats. Nat Neurosci. 2019;22(9):1383-1388.</Citation></Reference><Reference><Citation>Lee T , Li YR , Ingre C , et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Gen. 2011;20(9):1697-1700.</Citation></Reference><Reference><Citation>Becker LA , Huang B , Bieri G , et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367-371.</Citation></Reference><Reference><Citation>Elden AC , Kim HJ , Hart MP , et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069-1075.</Citation></Reference><Reference><Citation>Donde A , Sun M , Ling JP , et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138(5):813-826.</Citation></Reference><Reference><Citation>Raoul C , Abbas-Terki T , Bensadoun JC , et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med. 2005;11(4):423-428.</Citation></Reference><Reference><Citation>Foust KD , Salazar DL , Likhite S , et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148-2159.</Citation></Reference><Reference><Citation>Zhao M , Kim JR , van Bruggen R , Park J . RNA-binding proteins in amyotrophic lateral sclerosis. Mol Cells. 2018;41(9):818-829.</Citation></Reference><Reference><Citation>Hergesheimer RC , Chami AA , de Assis DR , et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142(5):1176-1194.</Citation></Reference><Reference><Citation>Picchiarelli G , Dupuis L . Role of RNA binding proteins with prion-like domains in muscle and neuromuscular diseases. Cell Stress. 2020;4(4):76-91.</Citation></Reference><Reference><Citation>Markmiller S , Soltanieh S , Server KL , et al. Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell. 2018;172(3):590-604.e13.</Citation></Reference><Reference><Citation>Shelkovnikova TA , An H , Skelt L , Tregoning JS , Humphreys IR , Buchman VL . Antiviral immune response as a trigger of FUS proteinopathy in amyotrophic lateral sclerosis. Cell Rep. 2019;29(13):4496-4508.e4.</Citation></Reference><Reference><Citation>Shelkovnikova TA , Dimasi P , Kukharsky MS , et al. Chronically stressed or stress-preconditioned neurons fail to maintain stress granule assembly. Cell Death Dis. 2017;8(5):e2788.</Citation></Reference><Reference><Citation>Shelkovnikova TA , Robinson HK , Southcombe JA , Ninkina N , Buchman VL . Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum Mol Gen. 2014;23(19):5211-5226.</Citation></Reference><Reference><Citation>Shelkovnikova TA , Peters OM , Deykin AV , et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288(35):25266-25274.</Citation></Reference><Reference><Citation>Cao X , Jin X , Liu B . The involvement of stress granules in aging and aging-associated diseases. Aging Cell. 2020;19(4):e13136.</Citation></Reference><Reference><Citation>Alberti S , Mateju D , Mediani L , Carra S . Granulostasis: protein quality control of RNP granules. Front Mol Neurosci. 2017;10:84.</Citation></Reference><Reference><Citation>Taylor JP , Brown RH , Cleveland DW . Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197-206.</Citation></Reference><Reference><Citation>Lechler MC , Crawford ED , Groh N , et al. Reduced insulin/IGF-1 signaling restores the dynamic properties of key stress granule proteins during aging. Cell Rep. 2017;18(2):454-467.</Citation></Reference><Reference><Citation>Klaips CL , Jayaraj GG , Hartl FU . Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217(1):51-63.</Citation></Reference><Reference><Citation>Mandrioli J , Mediani L , Alberti S , Carra S . ALS and FTD: where RNA metabolism meets protein quality control. Semin Cell Dev Biol. 2020;99:183-192.</Citation></Reference><Reference><Citation>Kroschwald S , Maharana S , Mateju D , et al. Promiscuous interactions and protein disaggregases determine the material state of stress-inducible RNP granules. eLife. 2015;4:e06807</Citation></Reference><Reference><Citation>Banani SF , Lee HO , Hyman AA , Rosen MK . Biomolecular condensates: organizers of cellular biochemistry. Nat Rev Mol Cell Biol. 2017;18(5):285-298.</Citation></Reference><Reference><Citation>Greenway MJ , Andersen PM , Russ C , et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet. 2006;38(4):411-413.</Citation></Reference><Reference><Citation>Kieran D , Sebastia J , Greenway MJ , et al. Control of motoneuron survival by angiogenin. J Neurosci. 2008;28(52):14056-14061.</Citation></Reference><Reference><Citation>Crivello M , O'Riordan SL , Woods I , et al. Pleiotropic activity of systemically delivered angiogenin in the SOD1(G93A) mouse model. Neuropharmacology. 2018;133:503-511.</Citation></Reference><Reference><Citation>Nardo G , Iennaco R , Fusi N , et al. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain. 2013;136(Pt 11):3305-3332.</Citation></Reference><Reference><Citation>Sheng J , Yu W , Gao X , Xu Z , Hu GF . Angiogenin stimulates ribosomal RNA transcription by epigenetic activation of the ribosomal DNA promoter. J Cell Physiol. 2014;229(4):521-529.</Citation></Reference><Reference><Citation>Li S , Chen Y , Sun D , et al. Angiogenin prevents progranulin A9D mutation-induced neuronal-like cell apoptosis through Cleaving tRNAs into tiRNAs. Mol Neurobiol. 2018;55(2):1338-1351.</Citation></Reference><Reference><Citation>Anderson P , Ivanov P . tRNA fragments in human health and disease. FEBS Lett. 2014;588(23):4297-4304.</Citation></Reference><Reference><Citation>Oosthuyse B , Moons L , Storkebaum E , et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet. 2001;28(2):131-138.</Citation></Reference><Reference><Citation>Lambrechts D , Poesen K , Fern&#xe1;ndez-Santiago R , et al. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet. 2009;46(12):840-846.</Citation></Reference><Reference><Citation>Azzouz M , Ralph GS , Storkebaum E , et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429(6990):413-417.</Citation></Reference><Reference><Citation>Azzouz M , Mazarakis N . Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases. Curr Gene Ther. 2004;4(3):277-286.</Citation></Reference><Reference><Citation>Kaspar BK , Llad&#xf3; J , Sherkat N , Rothstein JD , Gage FH . Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301(5634):839-842.</Citation></Reference><Reference><Citation>Dodge JC , Treleaven CM , Fidler JA , et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther. 2010;18(12):2075-2084.</Citation></Reference><Reference><Citation>Penn RD , Kroin JS , York MM , Cedarbaum JM . Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery. 1997;40(1):94-99.</Citation></Reference><Reference><Citation>Sokolov ME , Bashirov FV , Markosyan VA , et al. Triple-gene therapy for stroke: a proof-of-concept in vivo study in rats. Front Pharmacol. 2018;9:111</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>